<DOC>
	<DOCNO>NCT00500266</DOCNO>
	<brief_summary>To evaluate safety 13-valent pneumococcal conjugate vaccine ( 13vPnC ) elderly subject vaccinate one dose 23-valent pneumococcal polysaccharide vaccine ( 23vPS ) least 3 year study enrollment .</brief_summary>
	<brief_title>Study Evaluating Safety 13-Valent Pneumococcal Conjugate Vaccine Healthy Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>MAIN INCLUSION CRITERIA : Male female age 68 year old Determined medical history , physical examination , clinical judgment eligible study Documented vaccination 1 dos pneumococcal vaccine least 3 year study enrollment MAIN EXCLUSION CRITERIA : Known history severe reaction vaccine Documented S pneumoniae infection within past 5 year . Known suspected immunodeficiency receive treatment immunosuppressive therapy include cytotoxic agent systemic corticosteroid Serious chronic disorder include metastatic malignancy , severe chronic obstructive pulmonary disease require supplemental oxygen , endstage renal disease without dialysis , clinically unstable cardiac disease , disorder investigator 's opinion precludes subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>68 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>pneumococcal conjugate vaccine</keyword>
	<keyword>vaccine</keyword>
</DOC>